The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

Om denne artikel

Dato

6. sep. 2016

Resume

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.